🟢 Neurosense Therapeutics is trading 11.59% up in pre-market with no new company-specific announcement identified

Neurosense Therapeutics is trading 11.59% up at $0.51 in pre-market, with no new company-specific announcement identified for August 17, 2026, and the catalyst remains unclear.

• An August 13 CEO letter discussed delayed financing for the Phase 3 PARAGON ALS study and Nasdaq compliance efforts.
• The letter included a possible 1-for-4 to 1-for-40 reverse split if needed.
• Broader markets were modestly mixed, with Nasdaq up 0.59%; this does not establish a direct cause for the move.